Yuan Zhongxu, Ma Shuai, Yan Liang, Xu Man, Liu Dongquan, Wang Weicheng, Han Bowen, Chen Gan, Wang Zhengguang
Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, No. 218 Jixi Road, Shushan District, Hefei, 230022, Anhui, China.
Department of General Surgery, Anhui No. 2 Provincial People's Hospital, No. 1868 Dangshan and North Second Ring Road, Yaohai District, Hefei, 230041, Anhui, China.
Sci Rep. 2025 Jul 2;15(1):23570. doi: 10.1038/s41598-025-08431-2.
Surgical resection remains a potentially curative treatment option for pancreatic cancer (PC). However, the high rate of local tumor recurrence and poor prognosis severely limit its therapeutic efficacy. In this study, we report an injectable thermosensitive hydrogel platform (designated as NDP@MnO hydrogel) that exhibits excellent biocompatibility, photothermal performance, and wet adhesion properties, specifically designed for precise post-operative therapy. This thermosensitive system innovatively combines shear-thinning injectability, dopamine-mediated tissue adhesion, and MnO-enhanced photothermal ablation capabilities. By precisely targeting hyperthermia to the moist and irregular pancreatic resection margins during the sol-gel transition and subsequent exposure to an 808 nm laser, this approach can effectively and selectively eliminate residual tumor cells while minimizing collateral damage to adjacent healthy tissues. Notably, pre-clinical studies have demonstrated that this approach significantly reduces the locoregional recurrence rate in pancreatic cancer models, thereby offering a promising solution to the critical issue of postoperative recurrence.
手术切除仍然是胰腺癌(PC)潜在的治愈性治疗选择。然而,局部肿瘤高复发率和不良预后严重限制了其治疗效果。在本研究中,我们报告了一种可注射的热敏水凝胶平台(命名为NDP@MnO水凝胶),它具有优异的生物相容性、光热性能和湿粘附特性,专为精确的术后治疗而设计。这种热敏系统创新性地结合了剪切变稀可注射性、多巴胺介导的组织粘附性和MnO增强的光热消融能力。通过在溶胶-凝胶转变过程中以及随后暴露于808nm激光时,将热疗精确靶向到潮湿且不规则的胰腺切除边缘,这种方法可以有效且选择性地消除残留肿瘤细胞,同时将对相邻健康组织的附带损伤降至最低。值得注意的是,临床前研究表明,这种方法显著降低了胰腺癌模型中的局部区域复发率,从而为术后复发这一关键问题提供了一个有前景的解决方案。
ACS Appl Bio Mater. 2025-6-16
Arch Ital Urol Androl. 2025-6-30
ACS Appl Mater Interfaces. 2025-6-18
Proc Natl Acad Sci U S A. 2025-6-17
Acta Biomater. 2025-6-15
J Clin Oncol. 2024-9-10
Lancet Gastroenterol Hepatol. 2024-3
Mol Cancer. 2023-6-21
N Engl J Med. 2023-1-5